Prostate Cancer News and Research

Latest Prostate Cancer News and Research

New method allows single microchip to screen tens of thousands of genes simultaneously

RNA interference technology, which is used in cell biology, has revolutionised functional research of the gene products in the last ten years. VTT Technical Research Centre of Finland has developed a method which allows a single microchip to be used to screen the functions of tens of thousands of genes simultaneously by means of RNA interference.

20 Apr 2011

Sialix announces blood test results for early detection and treatment of breast cancer

Sialix, Inc. a pioneer in glycobiology, today announced the results of a study it participated in with researchers at the University of California, San Diego School of Medicine that could have significant impact in the prediction, early detection and treatment of cancer in humans.

20 Apr 2011

Adamis acquires cancer vaccine technology from UCSD

Adamis Pharmaceuticals Corporation (OTCBB: ADMP) today announced the completion of the acquisition of a unique patented cancer vaccine technology from the Regents of the University of California.

20 Apr 2011

OSU biophysicist leverages computer cluster to develop drug to block small protein molecule IL-6

An Ohio State biophysicist used a supercomputer to search thousands of molecular combinations for the best configuration to block a protein that can cause breast or prostate cancer.

20 Apr 2011

TCI forecasts cancer vaccine market to approach $3 billion in 2015

Technology Catalysts International (TCI), leading global consultants to the pharmaceutical industry, announced that research on cancer trends and development has identified cancer vaccines as a viable treatment option for a variety of cancers that currently have ineffective treatments. The potential of the cancer vaccine market is forecast to approach $3 billion in 2015.

20 Apr 2011

Ohio State biophysicist disrupts cellular messages through fragment-based drug design

An Ohio State biophysicist used a supercomputer to search thousands of molecular combinations for the best configuration to block a protein that can cause breast or prostate cancer.

19 Apr 2011

RaySearch receives order for its RayStation system from RISO

RaySearch Laboratories AB has received an order for its RayStation treatment planning system from RISO, the Radiotherapeutic Institute in Deventer, the Netherlands.

19 Apr 2011

BioSante, Aduro BioTech enter license agreement for GVAX cancer vaccines

Aduro BioTech, a clinical-stage immunotherapy company, has licensed GVAX Pancreas Cancer Vaccine and GVAX Prostate Cancer Vaccine BioSante Pharmaceuticals, Inc. in exchange for milestone and royalty payments after commercialization.

19 Apr 2011

BioSante licenses Pancreas and Prostate cancer vaccines to Aduro BioTech

BioSante Pharmaceuticals, Inc. today announced it has licensed its Pancreas Cancer Vaccine and Prostate Cancer Vaccine to Aduro BioTech, a clinical-stage immunotherapy company, solely for use in combination with Aduro's proprietary vaccine platform based on Listeria monocytogenes (Lm).

19 Apr 2011

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the publication of a case report in the peer-reviewed Journal of Clinical Oncology documenting the use of tamibarotene in the successful treatment of a patient with recurrent advanced-stage acute promyelocytic leukemia.

19 Apr 2011

First ever genome scan for womb cancer reveals genetic region that reduces risk of the disease

Scientists have carried out the first ever genome scan for womb cancer and discovered a genetic region that reduces risk of the disease, according to a study published in Nature Genetics.

18 Apr 2011

Penile extenders represent an effective lengthening method for men

Surgeons should encourage men who request penile lengthening surgery to try non-invasive methods first and, in some cases, consider therapy to help them feel more positive about their body.

18 Apr 2011

Ipsen, Active Biotech sign deal to co-develop and commercialize TASQ

Active Biotech AB and Ipsen announced today that they have entered into a broad partnership to co-develop and commercialize Active Biotech's investigational compound Tasquinimod "TASQ".

18 Apr 2011

EPO grants patent to OncoGenex OGX-427 for prostate cancer treatment

OncoGenex Pharmaceuticals, Inc., today announced that the European Patent Office has granted European Patent Number EP1545561 entitled "Oligonucleotides for Treatment of Prostate and other Cancers."

15 Apr 2011

The Wistar Institute, Advaxis enter research collaboration

Advaxis, Inc., the live, attenuated Listeria monocytogenes vaccine company, has entered into a research collaboration with the laboratory of Ellen Puré, Ph.D., professor/associate vice president for Academic Affairs at The Wistar Institute.

15 Apr 2011

Robotic prostatectomy speeds recovery

Robotic cancer surgery is being introduced into the public hospital system for the first time in Victoria. The Peter MacCallum Cancer Centre in Melbourne has been trialing the robotic key-hole surgery technology for the past six months.

12 Apr 2011

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today results from the two-year Phase III ALLEGRO study of laquinimod, an oral, once-daily, investigational immunomodulator for the treatment of relapsing forms of multiple sclerosis (MS). These data will be presented as late-breaking research at the Annual Meeting of the American Academy of Neurology (AAN).

12 Apr 2011

Study finds pelvic anatomy differences following RARP and open prostatectomy

Researchers from Boston University School of Medicine have concluded that the anatomy of the pelvis following robotic-assisted radical prostatectomy.

12 Apr 2011

Study shows neutralizing antibodies to C5a protein may prevent heart failure

New research published online in The FASEB Journal details research in rats and mice that offers hope for stopping the devastating, and often fatal, effects of sepsis in humans. In the study, University of Michigan researchers show how neutralizing the effects of a key protein fragment, called C5a, used by the immune system to attract white blood cells may ultimately prevent heart failure.

12 Apr 2011

PSA velocity is a poor predictor of prostate cancer

Researchers at Memorial Sloan-Kettering Cancer Center have found that change in PSA levels over time — known as PSA velocity — is a poor predictor of prostate cancer and may lead to many unnecessary biopsies.

11 Apr 2011